Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of TQB3454 in IDH1-mutant advanced biliary tract cancer
CTR20232257Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3454 in biliary cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2023; status: active.
02
Drugs
TQB3454
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20232257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232257.